COMMUNIQUÉS West-GlobeNewswire

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio
30/01/2024
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE [...]
EverythingALS Releases First Open Data From the Austen Speech Study
30/01/2024
Data from the citizen-driven initiative is made public for the first time SEATTLE, Jan. 30, 2024 (GLOBE NEWSWIRE) -- EverythingALS, a non-profit organization focused on research and technology, is pleased to announce [...]
Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP
30/01/2024
FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39% Successful deployment of the Group's strategy: Proprietary products up at 30% of revenues [...]
Eurobio Scientific : EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE
30/01/2024
EXERCICE 2023, CONFIRMATION DE LA TRANSFORMATION STRATEGIQUE Progression du chiffre d’affaires annuel cœur d’activité à +39% Succès du déploiement de la stratégie du Groupe : Produits propriétaires : 30% du Chiffre d’ [...]
Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults
30/01/2024
ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Defender Pharmaceuticals, Inc. (the “Company” or “Defender”), a privately held life sciences company based in St. Louis, today announced that the U.S. Food and Drug [...]
Novo Nordisk A/S - share repurchase programme
30/01/2024
Bagsværd, Denmark, 30 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Kairos Pharma Doses First Patient in Phase 2 Trial of Lead Drug Candidate ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
30/01/2024
LOS ANGELES, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd., a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces [...]
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
30/01/2024
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal [...]
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
30/01/2024
MINNEAPOLIS and CARMARTHENSHIRE, United Kingdom, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Magstim, the global leader in neuroscience research and treatment for mental health, has been awarded FDA clearance for the Horizon 3.0 [...]
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
30/01/2024
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on [...]
Generation Lab Emerges from Stealth with Funding Round and Mission to Extend the Human Healthspan – Waitlist for Its Clinically Driven At-Home Aging Test + Personalized Aging Intervention Opens Today
30/01/2024
With roots at University of California at Berkeley, startup aims to reduce healthcare costs and help people live longer, healthier lives SAN FRANCISCO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Generation Lab , which is [...]
Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use
30/01/2024
Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix’s development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE [...]
NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development
30/01/2024
Tom Hochuli will lead the organization as it renews its commitment to advancing cell and gene therapy MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that [...]
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
30/01/2024
WASHINGTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the [...]
Aeroflow Health Announces New Leadership Appointments Amid Company Growth
30/01/2024
The industry-leading durable medical equipment provider promotes three individuals to top corporate positions as Aeroflow continues its rampant growth ASHEVILLE, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aeroflow Health [...]
UTMD Reports Audited Year 2023 and Fourth Quarter Financial Performance
30/01/2024
SALT LAKE CITY, UT, Jan. 30, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – With Revenues 4% lower and Net Income and Earnings Per Share 1% higher than in 2022, Utah Medical Products, Inc. (Nasdaq: UTMD) achieved financial [...]
TytoCare to Host Major Health System Leaders for School Health Virtual Summit
30/01/2024
Leaders from Children’s Medical Center Dallas, Atrium Health, Cone Health, and others will share successful results of school health initiatives NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- TytoCare , a virtual care [...]
Talkspace and Bicycle Health Partner to Expand Access to Virtual Care for Patients with Opioid Use Disorder
30/01/2024
Millions Struggle with Substance Use Disorder and Mental Health: 7.7 million adults have a co-occurring substance use disorder and mental health condition. More than half receive treatment for neither ( Source ). Demand [...]
CorMedix Inc. Announces Commercial and Reimbursement Updates
30/01/2024
BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life [...]

Pages